GATWICK, England--(BUSINESS WIRE)--Systagenix (Gatwick, U.K.), announced today that it will launch EPIFIX® in the United States in March as part of a global distribution agreement reached with MiMedx Group, Inc. EPIFIX® is a human amniotic membrane allograft which has been shown to promote regeneration of soft tissues. Processed by Surgical Biologics, a MiMedx Group company, EPIFIX® is a minimally manipulated natural membrane that provides growth factors and an extracellular matrix for cellular ingrowth for enhanced healing.
